Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial

<p><strong>Background</strong> The use of the multicomponent meningococcal vaccine 4CMenB in the UK schedule at 2, 4, and 12 months of age has been shown to be 59·1% effective at preventing invasive group B meningococcal disease. Here, we report the first data on the immunogenicity...

Full description

Bibliographic Details
Main Authors: Davis, K, Valente Pinto, M, Andrews, NJ, Goldblatt, D, Borrow, R, Findlow, H, Southern, J, Partington, J, Plested, E, Patel, S, Holland, A, Matheson, M, England, A, Hallis, B, Miller, E, Snape, M
Format: Journal article
Language:English
Published: Elsevier 2021

Similar Items